EA202192860A1 - Сиалилированные гликопротеины - Google Patents

Сиалилированные гликопротеины

Info

Publication number
EA202192860A1
EA202192860A1 EA202192860A EA202192860A EA202192860A1 EA 202192860 A1 EA202192860 A1 EA 202192860A1 EA 202192860 A EA202192860 A EA 202192860A EA 202192860 A EA202192860 A EA 202192860A EA 202192860 A1 EA202192860 A1 EA 202192860A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mechanical stress
hsigg
resistant
sialylated glycoproteins
pharmaceutical
Prior art date
Application number
EA202192860A
Other languages
English (en)
Inventor
Сиддхеш Д. Патил
Original Assignee
Янссен Байотек, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк filed Critical Янссен Байотек, Инк
Publication of EA202192860A1 publication Critical patent/EA202192860A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Описаны фармацевтические препараты, содержащие гиперсиалилированные иммуноглобулины (hsIgG). Препараты устойчивы к механическому воздействию. Описанные в данном документе фармацевтические композиции обеспечивают фармацевтически приемлемые композиции hsIgG, которые устойчивы к механическому воздействию (например, если состав подвергается механическому воздействию, такому как встряхивание, например, во время транспортировки, при этом не происходит образования значительного количества невидимых частиц) и которые, таким образом, можно транспортировать и обрабатывать в жидкой форме.
EA202192860A 2019-04-18 2020-04-17 Сиалилированные гликопротеины EA202192860A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (1)

Publication Number Publication Date
EA202192860A1 true EA202192860A1 (ru) 2021-12-23

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192860A EA202192860A1 (ru) 2019-04-18 2020-04-17 Сиалилированные гликопротеины

Country Status (20)

Country Link
US (1) US20220211849A1 (ru)
EP (1) EP3955962A4 (ru)
JP (1) JP2022529168A (ru)
KR (1) KR20220002963A (ru)
CN (1) CN113795275A (ru)
AU (1) AU2020259492A1 (ru)
BR (1) BR112021020509A8 (ru)
CA (1) CA3137101A1 (ru)
CL (1) CL2021002668A1 (ru)
CO (1) CO2021013926A2 (ru)
CR (1) CR20210521A (ru)
EA (1) EA202192860A1 (ru)
EC (1) ECSP21078309A (ru)
IL (1) IL287306A (ru)
JO (1) JOP20210281A1 (ru)
MX (1) MX2021012710A (ru)
PE (1) PE20220383A1 (ru)
SG (1) SG11202110942SA (ru)
WO (1) WO2020215021A1 (ru)
ZA (1) ZA202109184B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
WO2022109327A1 (en) 2020-11-20 2022-05-27 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4662557B2 (ja) * 2003-06-09 2011-03-30 レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー 酸化還元反応による血漿タンパク質の結合特異性の改変方法
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
NZ599176A (en) * 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
SG176256A1 (en) * 2009-05-27 2012-01-30 Baxter Int A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
ES2802274T3 (es) * 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2014191240A1 (en) * 2013-05-29 2014-12-04 F. Hoffmann-La Roche Ag Quantitative control of sialylation
CN110167531A (zh) * 2017-01-11 2019-08-23 赛特瑞恩股份有限公司 稳定的液体调配物

Also Published As

Publication number Publication date
ZA202109184B (en) 2023-04-26
CL2021002668A1 (es) 2022-05-27
US20220211849A1 (en) 2022-07-07
KR20220002963A (ko) 2022-01-07
AU2020259492A1 (en) 2021-11-11
JP2022529168A (ja) 2022-06-17
WO2020215021A1 (en) 2020-10-22
JOP20210281A1 (ar) 2023-01-30
BR112021020509A8 (pt) 2023-01-10
SG11202110942SA (en) 2021-11-29
CN113795275A (zh) 2021-12-14
CO2021013926A2 (es) 2021-10-29
MX2021012710A (es) 2021-11-12
IL287306A (en) 2021-12-01
EP3955962A4 (en) 2022-12-14
ECSP21078309A (es) 2021-11-30
BR112021020509A2 (pt) 2022-03-15
CR20210521A (es) 2022-04-01
PE20220383A1 (es) 2022-03-18
CA3137101A1 (en) 2020-10-22
EP3955962A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
EA202192860A1 (ru) Сиалилированные гликопротеины
EA201992377A1 (ru) Стабильная композиция антитела
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
MX2020007697A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos.
AR108317A1 (es) Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
EP4223774A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
EA201990831A1 (ru) Смесительная система для получения косметического продукта и косметическая капсула
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
CL2017003208A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
EA201892446A1 (ru) Фармацевтическая композиция
MX2022001721A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.
WO2015058173A8 (en) Stable solid units and methods of making the same
PH12021550226A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA202192925A1 (ru) Твердые формы ингибитора glyt1
SA521430229B1 (ar) Il-33 صيغ ثابتة تحتوي على أجسام مضادة لـ
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
MX2022006130A (es) Composiciones inyectables de ácido ursodeoxicólico.
PH12020551618A1 (en) Erenumab compositions and uses thereof
SG10201807034XA (en) A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
MX2022005317A (es) Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
EA202090568A1 (ru) Составы копанлисиба
JOP20220097A1 (ar) كريزانليزوماب يحتوي على صياغات اجسام مضادة
EA202191254A1 (ru) Олигосахаридные препараты и композиции
DOP2024000066A (es) Dendrones peptídicos y métodos de uso de los mismos